Cellectis presented updated Phase 1 data for its allogeneic dual‑CAR‑T product eti‑cel at the 67th Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentation disclosed an overall response rate of 88 % and a complete response rate of 63 % in eight patients with relapsed or refractory non‑Hodgkin lymphoma who had received at least two prior lines of therapy.
These results build on earlier data from the same trial, which reported an 86 % overall response rate and a 57 % complete response rate in seven patients. The incremental improvement demonstrates robust efficacy in a population that has exhausted standard treatments, and the dual targeting of CD20 and CD22 offers broader coverage than single‑target CAR‑T therapies.
Cellectis introduced a low‑dose interleukin‑2 (IL‑2) support strategy to enhance CAR‑T expansion and persistence without increasing toxicity. The company will begin enrolling a new cohort with IL‑2 support in the first quarter of 2026, aiming to deepen response rates further.
Chief Medical Officer Adrian Kilcoyne emphasized that low‑dose IL‑2 could deepen the already high response rates seen in patients who have relapsed after multiple therapies, including CD19 CAR‑T. He also noted anticipation of the full Phase 1 dataset in 2026.
While eti‑cel remains in early development and has not yet received regulatory approval, the data represent a critical milestone that could accelerate the program’s progression toward later‑stage trials and potential market entry. Cellectis maintains a cash position that provides runway into the second half of 2027, supporting continued investment in the program.
Allogeneic dual CAR‑T therapies such as eti‑cel aim to provide off‑the‑shelf solutions, potentially addressing scalability and accessibility challenges faced by autologous CAR‑T products. The strong early efficacy signals position Cellectis favorably against competitors in the CAR‑T space.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.